Mary Jenkins | Senior Manager of Investor Relations |
Doug Ingram | President & Chief Executive Officer |
Ian Estepan | Executive Vice President & Chief Financial Officer |
Dallan Murray | Senior Vice President & Chief Commercial Officer |
Gilmore O'Neill | Executive Vice President of R&D & Chief Medical Officer |
Louise Rodino-Klapac | Executive Vice President & Chief Scientific Officer |
Tazeen Ahmad | Bank of America |
Anupam Rama | JP Morgan |
Brian Abrahams | RBC Capital Markets |
Salveen Richter | Goldman Sachs |
Gena Wang | Barclays |
Alethia Young | Cantor |
Matthew Harrison | Morgan Stanley |
Gil Blum | Needham & Company |
Ritu Baral | Cowen |
Colin Bristow | UBS |
Brian Skorney | Baird |
Hartaj Singh | Oppenheimer |
Yun Zhong | BTIG |
John Boyle | William Blair |
Danielle Brill | Raymond James |
Joseph Schwartz | SVB Leerink |
Good afternoon, ladies and gentlemen and welcome to the Sarepta Therapeutics Third Quarter 2021 Earnings Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. [Operator Instructions] As a reminder, today's program is being recorded. At this time, I'll turn the call over to Mary Jenkins, Senior Manager, Investor Relations.